Sexual function after permanent 125I-brachytherapy for prostate cancer.
We prospectively assessed patients' erectile function (EF) using the International Index of Erectile Function (IIEF) and a global assessment questionnaire (GAQ) following permanent 125I-brachytherapy for localized prostate cancer. Of 378 treated patients, 220 had a minimal 2-y follow-up and 131/220 were sexually active prior to brachytherapy, with an EF domain score of > or = 11 (study group). Patients were allowed sildenafil at any time of the study. The patients' mean EF score, without excluding patients who used sildenafil, dropped within 3 months after brachytherapy, recovered at the end of the first year and remained unchanged for at least up to 2 y after treatment regardless of the addition of neoadjuvant hormone therapy to 125I-brachytherapy. Analysis of the GAQ revealed that 80% of the patients were satisfied with their sexual function up to 3 y after treatment. Any detrimental effect of permanent brachytherapy with or without the addition of hormone therapy on EF is reversible, and recovery is expected at 1 y after treatment in most patients.
Mabjeesh
N
N
Department of Urology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. nicolam@tasmc.health.gov.il
Chen
J
J
Beri
A
A
Stenger
A
A
Matzkin
H
H
D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects*; D003131:Combined Modality Therapy; D007172:Erectile Dysfunction / Q000453:epidemiology / Q000209:etiology*; D005500:Follow-Up Studies; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000150:complications* / Q000532:radiotherapy*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D006728:Hormones; D007457:Iodine Radioisotopes